Expert Interview
Discussing the potential of semaglutide in chronic kidney disease and Novo Nordisk's recent decision to stop the kidney outcomes trial, FLOW based on interim analysis
Ticker(s): NVOInstitution: University of Miami
- Professor of Medicine, Molecular and Cellular Pharmacology, and Biochemistry at the University of Miami Miller School of Medicine, Chief of the Katz Family Division of Nephrology and Hypertension, and Director and Chair of the Peggy and Harold Katz Drug Discovery Center.
- Currently treats 200 patients with Chronic Kidney Disease and also manages patients with diabetic nephropathy, glomerular diseases, and inherited nephropathies.
- Primary research focus is related to mechanisms of proteinuria in kidney diseases, including kidney disease caused by exposure to cancer treatment.
How many patients do you currently treat with CKD?
Added By: chanell_admin- What percent of those typically also have Type 2 diabetes?
- Could you start by talking about what kind of role the GLP-1 agonists play currently in your practice?
- Is the FLOW trial result already having an impact on practice?
- What do you think about the individual components of the FLOW trial's composite endpoint and what are you looking for in terms of when they announce the details?
Added By: catalin_admin
- Do you think this drug could delay the onset of dialysis and what do you think about its mechanism of action?
- To what extent would the impact of this drug on nephrologists prescribing it change if patients are already getting Ozempic to manage their diabetes?
Added By: catalin_admin
- Was there a similar scenario with nephrologists prescribing SGLT2 inhibitors for diabetic patients?
- What would be a meaningful difference in terms of the EGFR endpoint in the FLOW trial?
Added By: catalin_admin
- How excited are you about the announcement of the trial stoppage and why?
- Do you think the market reaction towards dialysis providers is realistic or an overreaction?
Added By: catalin_admin
- Do you have any opinion on tirzepatide in terms of its potential impact on kidney disease compared to semaglutide?
- Any final thoughts regarding the FLOW trial or the future of kidney disease treatment?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
